Reply to: "Questioning Conclusions and Statements on the German HTA System: A Critical Perspective"
Clin Pharmacol Ther
.
2025 Jan;117(1):24.
doi: 10.1002/cpt.3452.
Epub 2024 Oct 1.
Authors
James Harnett
1
,
Julien Heidt
2
,
Ruben G W Quek
1
,
Laura Walsh
3
Affiliations
1
Health Economics & Outcomes Research, Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
2
Regulatory Science and Strategy, IQVIA, Falls Church, Virginia, USA.
3
Epidemiology and Drug Safety Practice, IQVIA, Cambridge, Massachusetts, USA.
PMID:
39350739
PMCID:
PMC11652801
DOI:
10.1002/cpt.3452
No abstract available
Publication types
Letter